Abu Dhabi: The world’s first phase III trials of an inactivated COVID-19 vaccine have been extended to Bahrain through Abu Dhabi-based G42 Healthcare.
The synthetic intelligence and cloud computing company sponsored UAE trials for the same vaccine, called 4Humanity, and the expansion to Bahrain will cause new volunteers to be recruited into the country.
One company said Tuesday that the publication of trials in Bahrain would strengthen ongoing collaboration between public aptitude institutions in the United Arab Emirates and Bahrain in the opposite fight against COVID-19. Bahrain’s new 4Humanity Recruitment Centre will seek to recruit 6,000 volunteers and is the third such facility in the Gulf after the Abu Dhabi National Exhibition Centre and the Alrain Qa Health Center in Sharjah.
“It was part of our initial plan to open several centers to make sure the larger ones have an effect and an opportunity for Americans to participate and enroll in the 4Humanity campaign. There has been an incredibly enthusiastic reaction from Bahrain’s Ministry of Health and other public fitness agencies to accompany us in rehearsals and inspire their communities to volunteer in the trials,” said Ashish Koshy, CEO of G42 Healthcare.
“The expansion will also increase the total number of other people who will take the check to allow similar numbers to other ongoing foreign trials in countries with much larger populations. We also anticipate an expansion of our network of centres in the UAE that will be announced shortly,” Koshy added.
All procedures adhere to foreign rules established through the World Health Organization (WHO) and the U.S. Food and Drug Administration (USFDA), officials said in the statement in Abu Dhabi.
Dear reader,
This segment is about life in the United Arab Emirates and data you cannot live without.
Sign up to read and complete gulfnews.com